Overview

Andrographis (Andrographis paniculata) is an annual herbaceous plant extensively cultivated in Southern and Southeast Asia, China, and parts of Africa and the Americas. Known as the "King of Bitters" for its intensely bitter taste, it has been used for centuries in traditional Ayurvedic and Traditional Chinese Medicine systems to treat a wide range of ailments including respiratory infections, digestive disorders, and febrile diseases. The primary bioactive constituents are diterpenoid lactones, particularly andrographolide, which is considered the main compound responsible for its therapeutic effects.

Clinical research has focused largely on andrographis for upper respiratory tract infections. Multiple trials suggest that standardized extracts, alone or combined with Eleutherococcus senticosus, may reduce the severity and duration of common cold symptoms. Andrographolide has demonstrated anti-inflammatory activity by suppressing pro-inflammatory cytokines and NF-κB signaling, as well as hepatoprotective, immunomodulatory, and antimicrobial properties in preclinical studies.

Beyond respiratory applications, emerging research has investigated andrographis for cardiovascular health, blood glucose regulation, and anticancer activity. Andrographolide has been shown to induce apoptosis in certain cancer cell lines through caspase activation and reactive oxygen species generation. While traditional use and preclinical data are extensive, large-scale clinical trials are still needed to establish definitive efficacy for most indications. Common side effects at standard doses are generally mild and gastrointestinal in nature.

Mechanism of Action

Primary Active Constituent — Andrographolide

Andrographis (Andrographis paniculata) owes its pharmacological activity primarily to andrographolide, a bicyclic diterpenoid lactone. Andrographolide's alpha-alkylidene gamma-butyrolactone moiety is critical for its biological activity, as it forms Michael adducts with cysteine residues on target proteins, acting as a covalent modifier of key signaling molecules (PMID: 20843245).

NF-kB Pathway Inhibition

The central anti-inflammatory mechanism involves direct binding to the p50 subunit of NF-kB, forming a covalent adduct at Cys62 in the DNA-binding domain. This prevents NF-kB from binding to promoter regions of pro-inflammatory genes. Additionally, andrographolide inhibits IKKbeta kinase activity, preventing IkB-alpha phosphorylation and degradation. The net effect is suppressed transcription of COX-2, iNOS, TNF-alpha, IL-1beta, and IL-6 (PMID: 15143854).

JAK-STAT Signaling Modulation

Andrographolide inhibits JAK2/STAT3 phosphorylation, reducing the transcription of STAT3 target genes involved in cell survival (Bcl-2, survivin) and proliferation (cyclin D1). This pathway modulation underlies both its anti-inflammatory properties and emerging interest in oncology applications (PMID: 22353613).

Immune System Activation

Paradoxically, at lower concentrations, andrographolide enhances cytotoxic T lymphocyte activity and NK cell function by promoting IL-2 production and CD markers expression. This dual immunomodulatory profile — anti-inflammatory at high concentrations, immunostimulatory at low concentrations — characterizes its adaptogenic properties (PMID: 19501277).

Antiviral Mechanisms

Andrographolide interferes with viral replication by inhibiting viral RNA-dependent RNA polymerase activity and upregulating interferon-stimulated genes through augmentation of the RIG-I/MDA5 innate antiviral sensing pathway.

Reconstitution Calculator

Research

Safety Profile

Common Side Effects

• Bitter taste and gastrointestinal upset (nausea, vomiting, diarrhea)
• Fatigue, headache, and dizziness
• Loss of appetite
• Allergic skin reactions (rash, urticaria) in sensitive individuals

Serious Concerns

• Hepatotoxicity: Case reports of acute liver injury associated with andrographis-containing supplements. Symptoms include jaundice, elevated transaminases, and fatigue. Liver injury is typically reversible upon discontinuation.
• Anaphylactic reactions have been reported rarely.
• May reduce fertility based on animal studies showing anti-spermatogenic effects at high doses.

Contraindications

• Known allergy to plants in the Acanthaceae family
• Active liver disease or history of drug-induced liver injury
• Pregnancy (traditionally used as an abortifacient in some cultures; animal data shows anti-fertility effects)
• Breastfeeding (insufficient safety data)
• Autoimmune conditions (may stimulate immune activity)

Drug Interactions

• Anticoagulants/antiplatelets (warfarin, aspirin, clopidogrel): Andrographis has antiplatelet activity; increased bleeding risk
• Antihypertensives: Additive blood pressure lowering
• Immunosuppressants (cyclosporine, tacrolimus): May counteract immunosuppressive therapy
• CYP substrates: Some evidence of CYP1A2 and CYP3A4 modulation; may alter drug metabolism

Special Populations

• Pediatric: Limited safety data; not recommended for children under 12
• Geriatric: Use with caution due to polypharmacy risks and hepatic vulnerability
• Surgical patients: Discontinue at least 2 weeks before surgery due to bleeding risk

Monitoring

• Liver function tests (ALT, AST, bilirubin) at baseline and periodically during use
• Monitor for signs of bleeding if co-administered with anticoagulants
• Blood pressure monitoring in hypertensive patients

Pharmacokinetic Profile